Related Experiment Videos
Bcl-2 expression and other clinicopathologic parameters in uterine leiomyosarcoma
Klaus Bodner1, Barbara Bodner-Adler, Oliver Kimberger
1Departments of Gynecology & Obstetrics, University of Vienna Medical School, Vienna, Austria. klausbodner@yahoo.com
Wiener Klinische Wochenschrift
|March 25, 2004
Summary
Bcl-2 expression in uterine leiomyosarcomas (LMS) is linked to better survival rates and less vascular-space involvement. This suggests bcl-2 may be a positive prognostic marker in uterine LMS patients.
Area of Science:
- Oncology
- Molecular Biology
- Gynecologic Pathology
Background:
- The bcl-2 protein regulates cell cycle and apoptosis, potentially influencing tumor growth.
- Previous research indicated bcl-2's prognostic significance in uterine leiomyosarcomas (LMS).
- Limited studies exist on bcl-2 expression in uterine LMS.
Purpose of the Study:
- To investigate bcl-2 protein expression in uterine LMS.
- To determine the prognostic value of bcl-2 expression in uterine LMS.
- To evaluate associations between bcl-2 expression and clinicopathologic parameters.
Main Methods:
- Immunohistochemical analysis of bcl-2 expression on paraffin-embedded uterine LMS tissue from 21 patients.
- Correlation of bcl-2 expression with FIGO stage, patient age, vascular-space involvement, and disease recurrence.
Main Results:
- Bcl-2 was expressed in 57% of uterine LMS cases (12/21).
- A significant negative correlation was observed between bcl-2 expression and vascular-space involvement (p=0.04).
- Patients with bcl-2-positive LMS showed significantly longer overall survival (p=0.03).
Conclusions:
- Bcl-2 expression is negatively correlated with vascular-space involvement in uterine LMS.
- Positive bcl-2 expression is associated with improved survival rates in uterine LMS patients.
- Bcl-2 expression may play a role in the prognosis of uterine LMS, despite study limitations.